Photo: investors.comThe Holy Grail In Cancer? FDA Panel Backs Blood Tests.
Reported by investors.com, not nibnow. We are not the publisher of this story, only the source is.
FDA panel support for a blood screening test could signal a significant shift in how cancer is detected, potentially making early diagnosis more accessible and less invasive for patients.
An FDA advisory committee convened to examine a company’s blood‑based screening assay that is intended to detect cancer. During the meeting, panel members reviewed the test’s scientific basis, the data submitted by the developer, and the potential role such a blood test could play in early cancer detection. The discussion focused on the assay’s performance characteristics, the regulatory pathway, and the criteria that would need to be met before the test could receive market authorization. The panel’s deliberations represent a key step in the regulatory evaluation of this emerging diagnostic technology.
- •The final FDA decision on whether to approve or reject the blood screening test.
- •Potential updates to clinical guidelines regarding the use of liquid biopsies for early cancer detection.